GLP-3 (10 mg): Retatrutide Peptide Research Guide

What Is GLP-3 (Retatrutide)?

GLP-3 is a commercial name commonly associated with retatrutide, also identified by the research code LY3437943. Retatrutide is an investigational synthetic peptide developed to interact with three important metabolic hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.

Unlike compounds that target only one receptor, retatrutide is designed as a triple agonist. This makes it an important subject in scientific investigations involving metabolic signaling, receptor interactions, and energy regulation.

The GLP-3 (10 mg) listing identifies the stated product quantity. Its exact identity, composition, and quality should be verified through the manufacturer’s specifications and batch-specific analytical documentation.

Understanding the Three Receptor Targets

Retatrutide’s research profile is based on its interaction with three receptor systems.

 GLP-1 Receptor

The GLP-1 receptor is involved in glucose regulation, insulin secretion, appetite-related signaling, and gastrointestinal processes. It is an important target in metabolic research because of its role in communication between the digestive system and other organs.

 GIP Receptor

The glucose-dependent insulinotropic polypeptide receptor is associated with glucose-dependent insulin secretion and broader metabolic signaling. Researchers investigate this pathway to understand how GIP-related activity interacts with other hormonal systems.

 Glucagon Receptor

The glucagon receptor participates in the regulation of energy metabolism, particularly processes involving glucose production and energy availability. Its inclusion gives retatrutide a distinct research profile compared with single- or dual-receptor compounds.

Why Is Retatrutide Called a Triple Agonist?

A receptor agonist is a substance that activates a particular receptor. Retatrutide is described as a triple agonist because it has activity at the GIP, GLP-1, and glucagon receptors.

These three receptor systems are involved in interconnected metabolic processes. Studying their combined activation helps researchers investigate how multiple hormonal pathways communicate and influence metabolic regulation.

This multi-receptor design is one reason retatrutide has attracted considerable scientific attention. However, its investigational status means that research findings should not be interpreted as proof of established long-term safety or general clinical suitability.

GLP-3 and Metabolic Research

Metabolic research examines how the body processes nutrients, regulates energy, and maintains glucose balance. It includes the study of hormones, receptors, cellular communication, and interactions between different organ systems.

Retatrutide provides researchers with a compound for investigating several related pathways within one experimental model.

Areas of scientific investigation include:

• GIP, GLP-1, and glucagon receptor activity.
• Incretin-related signaling pathways.
• Glucose and energy metabolism.
• Hormonal communication and receptor interactions.
• Metabolic regulation in experimental models.
• Multi-receptor peptide pharmacology.

These are research areas, not guaranteed outcomes or claims about the effects of this particular product.

GLP-3 (10 mg) Product Information

GLP-3 (10 mg) is a research product commonly marketed under the retatrutide designation. The 10 mg label represents the stated quantity and should not be interpreted as a recommended dose or personal-use instruction.

Researchers and laboratory professionals should review the supplier’s documentation before evaluating the material. Relevant information includes:

• Verified compound identity.
• Amino acid sequence and molecular specifications.
• Batch-specific purity results.
• Certificate of Analysis (COA), where available.
• Manufacturing and quality-control documentation.
• Physical form and supplier handling information.

A product name or advertised purity percentage alone does not establish identity, quality, or suitability for a particular experiment.

Investigational Status and Research Considerations

Retatrutide remains an investigational compound and should not be confused with an approved prescription medicine. Clinical-trial findings are specific to the compound, formulation, study population, and conditions investigated. They do not establish that an independently marketed research product is approved or appropriate for human use.

The GLP-3 (10 mg) product described here is intended strictly for laboratory research and educational purposes. It is not intended for human or veterinary consumption, injection, self-experimentation, diagnosis, prevention, or treatment of any medical condition.

Conclusion

GLP-3, commonly marketed as retatrutide, is an investigational triple-receptor agonist studied for its interactions with GIP, GLP-1, and glucagon receptors. Its multi-receptor design makes it relevant to research involving metabolic signaling, hormonal communication, and peptide pharmacology. The GLP-3 (10 mg) listing provides a reference for research-oriented documentation, with verified identity and batch-specific quality information remaining essential considerations.